Tame Impala Announce 2021 ‘Phase 1 Rushium® Trials’ Tour

/ By / Concerts, Tours, & Fests, Events

Tame Impala are officially returning to the United States in 2021 for a tour. A press release gets a little clever with the announcement, stating that AionWell® L.T.d, a privately held Australian biopharmaceutical company, will grant Tame Impala equity in the company under the condition that they participate in the Phase I trial of Rushium®. The trials require that they perform a combination of solo headline shows and music festivals from September through November, 2021.

Unfortunately, the Australian outfit was not able to fully reschedule their planned tour for 2020 but those shows that were able to be included in the 2021 itinerary will have their tickets honored – refunds will be issued for shows no longer happening.

Check out the full Dates of Phase 1 Rushium® Trials (“Tame Impala” Tour) below.

Tame Impala 2021 Tour Dates

9/4/21 – Bonnaroo Festival – Manchester, TN
9/7/21 – United Center – Chicago, IL
9/10/21 – The Gorge – George, WA
9/12/21 – Moda Center – Portland, OR
9/15/21 – Chase Center – San Francisco, CA
9/17/21 – Life is Beautiful Festival – Las Vegas, NV
9/18/21 – Gila River Arena – Glendale, AZ
9/20/21 – Ball Arena – Denver, CO
9/23/21 – Capital One Arena – Washington, DC
9/25/21 – Firefly Festival – Dover, DE
9/28/21 – State Farm Arena – Atlanta, GA
10/31/21 – Outside Lands Festival – San Francisco, CA
11/2/21 – Hollywood Bowl – Los Angeles, CA
11/3/21 – Hollywood Bowl, Los Angeles, CA
11/7/21 – Frank Erwin Center – Austin, TX
11/9/21 – American Airlines Center, Dallas, TX
DATE TBD – Scotiabank Arena – Toronto, ON
From the press release:
AionWell® L.T.d, a privately held Australian biopharma ceutical company focused on the development of recombinant stabilization and expansion of cellular space regrowth, has announced today that Kevin Parker, D.B.A. “Tame Impala,”  has acquired minority equity interest in AionWell® L.T.d and secured an option to acquire the remaining equity in the company. The option becomes exercisable upon the completion of Phase I trial of Rushium® in the treatment of Acute Time Metagrobolization in Cells (ATMiC) within patients from 16 to 95 years of age. ATMiC is a common cellular condition within the brain’s Suprachiasmatic nucleus, much of the research into this condition is cutting edge and still being performed. Based on the current findings, ATMiC could affect up to half of the pop ulation. Currently there are no medications approved for this condition and the only treatment is supportive care and third dose mesothermal procedure.

More like this

Scroll to Top